1. Home
  2. KYN vs HRMY Comparison

KYN vs HRMY Comparison

Compare KYN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

HOLD

Current Price

$11.84

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$38.50

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KYN
HRMY
Founded
2004
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KYN
HRMY
Price
$11.84
$38.50
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$51.33
AVG Volume (30 Days)
561.5K
789.9K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
8.99%
N/A
EPS Growth
N/A
50.44
EPS
0.71
3.17
Revenue
N/A
$825,944,000.00
Revenue This Year
N/A
$23.11
Revenue Next Year
N/A
$16.15
P/E Ratio
$13.79
$12.79
Revenue Growth
N/A
21.13
52 Week Low
$7.84
$25.52
52 Week High
$9.88
$40.93

Technical Indicators

Market Signals
Indicator
KYN
HRMY
Relative Strength Index (RSI) 44.26 64.34
Support Level $12.01 $38.12
Resistance Level $12.52 $40.87
Average True Range (ATR) 0.20 1.25
MACD -0.04 0.00
Stochastic Oscillator 5.88 62.25

Price Performance

Historical Comparison
KYN
HRMY

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: